Drug Profile
Pegylated recombinant human hyaluronidase companion diagnostic - Halozyme
Alternative Names: PEG PH20 companion diagnostic - Halozyme; PEG rHuPH-20 companion diagnostic - Halozyme; Pegylated rHuPH20 companion diagnostic - HalozymeLatest Information Update: 13 Jul 2021
Price :
$50
*
At a glance
- Originator Halozyme Therapeutics
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Pancreatic cancer
Most Recent Events
- 13 Jul 2021 Ventana Medical Systems is now called Roche Tissue Diagnostics
- 04 Nov 2019 Discontinued - Phase-I for Pancreatic cancer (Diagnosis) in Russia (unspecified route) due to organisational restructuring
- 04 Nov 2019 Discontinued - Phase-II for Pancreatic cancer (Diagnosis) in USA (unspecified route) due to organisational restructuring